Literature DB >> 33777018

Immune Soluble Factors in the Cerebrospinal Fluid of Progressive Multiple Sclerosis Patients Segregate Into Two Groups.

Gloria Donninelli1, Valeria Studer2,3, Laura Brambilla2, Chiara Zecca4,5, Daniele Peluso6, Alice Laroni7,8, Daniele Michelis7, Renato Mantegazza2, Paolo Confalonieri2, Elisabetta Volpe1.   

Abstract

Primary-progressive (PP) and secondary-progressive (SP) multiple sclerosis (MS) are characterized by neurological deficits caused by a permanent neuronal damage, clinically quantified by the expanded disability status scale (EDSS). Neuronal tissue damage is also mediated by immune infiltrates producing soluble factors, such as cytokines and chemokines, which are released in the cerebrospinal fluid (CSF). The mechanisms regulating the production of a soluble factor are not completely defined. Using multiplex bead-based assays, we simultaneously measured 27 immune soluble factors in the CSF collected from 38 patients, 26 with PP-MS and 12 with SP-MS. Then, we performed a correlation matrix of all soluble factors expressed in the CSF. The CSF from patients with PP-MS and SP-MS had similar levels of cytokines and chemokines; however, the stratification of patients according to active or inactive magnetic resonance imaging (MRI) unveils some differences. Correlative studies between soluble factors in the CSF of patients with PP-MS and SP-MS revealed two clusters of immune mediators with pro-inflammatory functions, namely IFN-γ, MCP-1, MIP-1α, MIP-1β, IL-8, IP-10, and TNF-α (group 1), and anti-inflammatory functions, namely IL-9, IL-15, VEGF, and IL-1ra (group 2). However, most of the significant correlations between cytokines of group 1 and of group 2 were lost in patients with more severe disability (EDSS ≥ 4) compared to patients with mild to moderate disability (EDSS < 4). These results suggest a common regulation of cytokines and chemokines belonging to the same group and indicate that, in patients with more severe disability, the production of those factors is less coordinated, possibly due to advanced neurodegenerative mechanisms that interfere with the immune response.
Copyright © 2021 Donninelli, Studer, Brambilla, Zecca, Peluso, Laroni, Michelis, Mantegazza, Confalonieri and Volpe.

Entities:  

Keywords:  cerebrospinal fluid; chemokines; cytokines; expanded disability status scale; progressive multiple sclerosis

Year:  2021        PMID: 33777018      PMCID: PMC7988186          DOI: 10.3389/fimmu.2021.633167

Source DB:  PubMed          Journal:  Front Immunol        ISSN: 1664-3224            Impact factor:   7.561


  39 in total

1.  Increased cerebrospinal fluid concentrations of the chemokine CXCL13 in active MS.

Authors:  F Sellebjerg; L Börnsen; M Khademi; M Krakauer; T Olsson; J L Frederiksen; P S Sørensen
Journal:  Neurology       Date:  2009-12-08       Impact factor: 9.910

Review 2.  Multiple sclerosis.

Authors:  Alan J Thompson; Sergio E Baranzini; Jeroen Geurts; Bernhard Hemmer; Olga Ciccarelli
Journal:  Lancet       Date:  2018-03-23       Impact factor: 79.321

3.  IP-10 and MCP-1 levels in CSF and serum from multiple sclerosis patients with different clinical subtypes of the disease.

Authors:  Elio Scarpini; Daniela Galimberti; Pierluigi Baron; Raffaella Clerici; Marco Ronzoni; Giancarlo Conti; Guglielmo Scarlato
Journal:  J Neurol Sci       Date:  2002-03-15       Impact factor: 3.181

4.  Protective effect of the interleukin-1 receptor antagonist (IL-1ra) on experimental allergic encephalomyelitis in rats.

Authors:  D Martin; S L Near
Journal:  J Neuroimmunol       Date:  1995-09       Impact factor: 3.478

5.  Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS).

Authors:  J F Kurtzke
Journal:  Neurology       Date:  1983-11       Impact factor: 9.910

6.  Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria.

Authors:  Chris H Polman; Stephen C Reingold; Brenda Banwell; Michel Clanet; Jeffrey A Cohen; Massimo Filippi; Kazuo Fujihara; Eva Havrdova; Michael Hutchinson; Ludwig Kappos; Fred D Lublin; Xavier Montalban; Paul O'Connor; Magnhild Sandberg-Wollheim; Alan J Thompson; Emmanuelle Waubant; Brian Weinshenker; Jerry S Wolinsky
Journal:  Ann Neurol       Date:  2011-02       Impact factor: 10.422

7.  Identification of a unique TGF-β-dependent molecular and functional signature in microglia.

Authors:  Oleg Butovsky; Mark P Jedrychowski; Craig S Moore; Ron Cialic; Amanda J Lanser; Galina Gabriely; Thomas Koeglsperger; Ben Dake; Pauline M Wu; Camille E Doykan; Zain Fanek; Liping Liu; Zhuoxun Chen; Jeffrey D Rothstein; Richard M Ransohoff; Steven P Gygi; Jack P Antel; Howard L Weiner
Journal:  Nat Neurosci       Date:  2013-12-08       Impact factor: 24.884

8.  Cerebrospinal Fluid and Blood Cytokines as Biomarkers for Multiple Sclerosis: A Systematic Review and Meta-Analysis of 226 Studies With 13,526 Multiple Sclerosis Patients.

Authors:  Zhile Bai; Duanduan Chen; Luyao Wang; Yu Zhao; Tiantian Liu; Yun Yu; Tianyi Yan; Yong Cheng
Journal:  Front Neurosci       Date:  2019-10-04       Impact factor: 4.677

9.  Characteristic cerebrospinal fluid cytokine/chemokine profiles in neuromyelitis optica, relapsing remitting or primary progressive multiple sclerosis.

Authors:  Takuya Matsushita; Takahisa Tateishi; Noriko Isobe; Tomomi Yonekawa; Ryo Yamasaki; Dai Matsuse; Hiroyuki Murai; Jun-Ichi Kira
Journal:  PLoS One       Date:  2013-04-18       Impact factor: 3.240

10.  Feasibility of the use of combinatorial chemokine arrays to study blood and CSF in multiple sclerosis.

Authors:  Keith R Edwards; Jaya Goyal; Tatiana Plavina; Julie Czerkowicz; Susan Goelz; Ann Ranger; Diego Cadavid; Jeffrey L Browning
Journal:  PLoS One       Date:  2013-11-20       Impact factor: 3.240

View more
  3 in total

1.  Interleukin 6 SNP rs1818879 Regulates Radiological and Inflammatory Activity in Multiple Sclerosis.

Authors:  Antonio Bruno; Ettore Dolcetti; Federica Azzolini; Alessandro Moscatelli; Stefano Gambardella; Rosangela Ferese; Francesca Romana Rizzo; Luana Gilio; Ennio Iezzi; Giovanni Galifi; Angela Borrelli; Fabio Buttari; Roberto Furlan; Annamaria Finardi; Francesca De Vito; Alessandra Musella; Livia Guadalupi; Georgia Mandolesi; Diego Centonze; Mario Stampanoni Bassi
Journal:  Genes (Basel)       Date:  2022-05-17       Impact factor: 4.141

2.  Effect of Multiple Sclerosis Cerebrospinal Fluid and Oligodendroglia Cell Line Environment on Human Wharton's Jelly Mesenchymal Stem Cells Secretome.

Authors:  Karolina Salwierak-Głośna; Paweł Piątek; Małgorzata Domowicz; Mariola Świderek-Matysiak
Journal:  Int J Mol Sci       Date:  2022-02-16       Impact factor: 5.923

Review 3.  Autoreactive lymphocytes in multiple sclerosis: Pathogenesis and treatment target.

Authors:  Rongzeng Liu; Shushu Du; Lili Zhao; Sahil Jain; Kritika Sahay; Albert Rizvanov; Vera Lezhnyova; Timur Khaibullin; Ekaterina Martynova; Svetlana Khaiboullina; Manoj Baranwal
Journal:  Front Immunol       Date:  2022-09-23       Impact factor: 8.786

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.